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Abstract
Background: Levosimendan exerted favorable effects on the initial outcome in the treatment of ventricular
fibrillation cardiac arrest. This study investigated the efficacy of levosimendan in the treatment of asphyxia-
induced cardiac arrest in rats.
Methods: Animals underwent asphyxial cardiac arrest/cardiopulmonary resuscitation, randomized to three
treatment groups: epinephrine (10 μg/kg) supplemented with levosimendan (bolus 12 μg/kg and infusion for
1 h, EL group); epinephrine only (10 μg/kg, E group), or levosimendan only (bolus 12 μg/kg and infusion for 1 h,
L group). The resuscitation success rate, wet-to-dry ratio of lung, and rate of alveolar and blood gas analysis
were recorded.
Results: 10 rats in the EL group, 8 in the E group, and 2 in the L group showed an initial return of spontaneous
circulation (P < 0.001); among them, 10, 4, and 2 rats survived at the end of a 60-min observation period from each
group, respectively (P = 0.001). The coronary perfusion pressure in the EL group was higher than that of either the E or
L group (P < 0.05). The lung wet-to-dry weight ratio and rate of damaged alveoli were lower in the EL group than the E
group (P < 0.05).
Conclusions: In the early stage of resuscitation for asphyxia-induced cardiac arrest in rats, levosimendan supplemented
with epinephrine can significantly increase coronary perfusion pressure, reduce lung injury, and ultimately enhance the
survival rate.
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Background
Cardiac arrest (CA) is the most devastating adverse car-
diac event, and it causes approximately 325,000 deaths
each year in the United States [1]. Asphyxia, a result
from loss of the airway, is a rare but significant cause of
serious complications, and can lead to an asphyxia-
induced CA. Epinephrine is a standard of medication in
resuscitation of CA and it has been incorporated into
the American Heart Association guidelines for cardio-
pulmonary resuscitation since 1973. It exhibits potent
vasoconstriction effect, increases coronary perfusion
pressure (CPP), and facilitates return of spontaneous cir-
culation (ROSC) [2, 3] However, the effects of sole epi-
nephrine in the setting of CA have always been
questioned because it increases myocardial oxygen
demand through its beta adrenergic receptors [4], which
cause post-resuscitation myocardial dysfunction [5]. It
also exerts acute, adverse effects on pulmonary oxygen
exchange, which then leads to severe pulmonary edema
and acidosis [6]. These unwarranted side effects have a
negative impact on long-term survival. Therefore, the
American Heart Association guidelines have now dis-
couraged large doses of epinephrine for adult advanced
cardiovascular life support during resuscitation [7]. In
clinical practice, however, epinephrine is still the preferred
agent during cardiopulmonary resuscitation (CPR).
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Levosimendan is a unique inodilator that exerts ino-
tropic effects principally via binding to the Ca2+-satu-
rated troponin C of the myocardial thin filament [8].
Unlike classic inotropic agents, it has inotropic action
without increasing myocardial oxygen consumption dur-
ing infusion in congestive heart failure [9]. Furthermore,
levosimendan also has vasodilatory effects mediated by
the opening of ATP-sensitive potassium channels in the
sarcolemmal membrane of vascular smooth muscle cells
[10], which decreases the central venous pressure and the
systolic and diastolic pressures of the right atrium [11].
There are conflicting reports in the literature regarding
the efficacy of levosimendan in the treatment of CA. Kelm
et al. [12] reported that levosimendan combined with
vasopressin administration during CPR resulted in
increased cerebral blood flow and improved neurological
outcome, but could not facilitate ROSC in a rat model of
asphyctic CA. The recent research reported by Kosmidou
et al. [13] showed that levosimendan combined with epi-
nephrine only improved 24-h neurological outcome, but
there was no evidence of improvement of initial resuscita-
tion success and the final survival rate in a swine model of
asphyctic CA. However, Koudouna et al. [14] reported
that a combination of epinephrine and levosimendan in a
swine model of ventricular fibrillation CA significantly im-
proved CPP and initial resuscitation success. Thus, it is
not clear whether levosimendan could play a beneficial
role in the process of resuscitation; additional studies are
necessary for providing further evidence to confirm the
benefit of levosimendan during resuscitation with different
animal CA models.
We hypothesized that levosimendan combined with
epinephrine can improve post-resuscitation outcomes
and survival rates in the treatment of asphyxia-induced
CA, and designed a double-blind, prospective, random-
ized study using a rat model after asphyctic CA. The pri-
mary end point assessed was the survival rate, and the
secondary end points were the rate of ROSC, the lung
wet-to-dry weight ratio, and hemodynamic parameters.
Methods
Experimental animals and groups
All studies were approved by the Ethics Committee of
the Wenzhou Medical University (Wenzhou, China).
Healthy Sprague-Dawley male rats, 7 to 8 weeks old, 300
to 350 gin weight, were divided randomly into three
experimental groups (10rats/group) randomly: the epi-
nephrine (Jinyao Amino Acid Co., Ltd., Tianjin, China)
and levosimendan (Qilu pharmaceutical Co., Ltd.,
Shandong, China) treatment group (EL), the epinephrine
(10 μg/kg in 2.5 ml of volume) combined with levosi-
mendan [bolus during CPR (12 μg/kg in 1.2 ml of vol-
ume) and infusion for 1 h (0.3 μg/kg/min in 0.03 ml of
volume)], and the epinephrine-only treatment group (E),
epinephrine (10 μg/kg in 2.5 ml of volume) administered
with saline 0.9% [bolus during CPR and infusion for 1 h
(equivalent fluid volume)] or levosimendan-only treat-
ment group (L), saline 0.9% (equivalent fluid volume
bolus) administered with levosimendan [bolus 12 μg/kg
in 1.2 ml of volume and infusion for 1 h (0.3 μg/kg/min
in 0.03 ml of volume)].
Animal preparation
All rats were fasted for 12 h before the experiment
began and were given access to water ad libitum. They
were anesthetized with an intraperitoneal injection of
urethane (20%, 200 mg/kg). A tracheal intubation was
performed via tracheotomy and rats were connected to
the rodent volume-controlled ventilator (tidal volume,
8 ml/kg; FiO2,1.0; respiratory rate, 75–80 breaths/min;
inspiratory/expiratory ratio, 2:3; HX-300; TME Technol-
ogy Co., Ltd., Chengdu, China) [15, 16]. The right fem-
oral artery was cannulated for the sampling of blood and
continuous arterial pressure monitoring. Intravenous
drug administration took place through drug right fem-
oral vein cannulation. A third catheter was inserted into
the left jugular vein and then advanced into the right
atrium for measuring the right atrial pressure. Electro-
cardiography, using three subcutaneous needle elec-
trodes, continuously recorded arterial and right atrial
pressure throughout the duration of the experiments
with a MedLab data archiving and retrieval system using
U/4C051 (Nanjing Medease Science and Technology
Co., Ltd., Jiangsu, China). All animals were stabilized for
15 min after completion of invasive procedures. There-
after, CPP, mean arterial pressure (MAP), heart rate
(HR), and rate-pressure product (RPP) were recorded.
CPP was calculated as the difference between decom-
pression diastolic aortic and time-coincident right atrial
pressure and was measured at the end of each minute of
precordial compression [14]. Arterial blood gases
(ABGs) were also collected [17].
Experimental model
The asphyxia-induced CA model was quoted from the
experiment performed by McCaul et al. [18]. After a
stabilization periodof15 min, CA was achieved by stop-
ping mechanical ventilation, which resulted in CA after
approximately 3 min. CA was indicated by a decrease in
MAP below 10 mmHg. All rats in each group were led
to CA.
Resuscitation protocol
Resuscitation began 1 min after onset of CA and was
established by starting the ventilator (FiO2 1.0, VT 8 ml/
kg, rate 75–80 min−1), beginning external chest com-
pressions (approximately 300 min−1 at a depth of 1 cm),
and through intravenous administration of medication.
Wu et al. BMC Anesthesiology  (2017) 17:18 Page 2 of 8
Effective resuscitation (ROSC) was defined as a native
RPP more than 20% of baseline value for 1 min [15, 19].
Chest compressions continued until spontaneous circu-
lation returned or an elapsed time of 60 min without
successful resuscitation; no ventilation changes were
made before or after resuscitation. We used an adjust-
able infrared sensor maintain body temperature at 37 °C
to 39 °C, and we preheated all intravenous solutions to
37 °C before infusion. At the end of the 60-min resusci-
tation period, the animals were killed by anesthetic over-
dose, and the excised lung samples were taken for
subsequent analysis.
Measurements
We dynamically documented the values of SBP, MAP,
and HR in all three groups and calculated the RPP and
CPP of the survivors during the 60-min resuscitation
period. In addition, we recorded the time to CA, the
time to first heartbeat, and the time to ROSC. ROSC
and rats surviving at 60 min were also recorded. The
rate of successful resuscitation and survival at 60 min
was calculated (rate of ROSC = number of rats displaying
ROSC/total number of rats; survival at 60 min = number
of rats survived at 60 min/total number of rats). Finally,
arterial blood gas analyses were performed.
The wet-to-dry ratio of the lung and pathology
The animals were sacrificed after CPR. The lobe of the
left lung was weighed and dried, and we calculated the
lung wet-to-dry weight ratio. We fixed the middle lobe
of the right lungin10% formalin fixative, created paraffin-
embedded slices, and used hematoxylin and eosin stain
for observation [15]. Fifty views (400×) were selected ran-
domly in each sample by using light microscopy. In every
view, the total number of pulmonary alveoli and the num-
ber damaged were counted. We then calculated the ratio
of damaged lung alveoli to the total number of lung al-
veoli. We defined the alveolus as injured when more than
two inflammatory cells or two red blood cells were evident
in one pulmonary alveolus [15, 20].
Statistical analysis
Based on our pre-test, we used the Power Sample Size
(PASS11.0) software program for power analysis and
compared the survival rates among the experimental
groups. In our preliminary study, 18 rats were used, with
6 rats in each group. There were 6, 1, and 1 rat in
groups EL, E, and L that survived to 60 min, respect-
ively. The survival rate was 100, 16.7, and 16.7%,
respectively. We set the power at 0.8; the significance
criterion was 0.017. As a result, we needed 8 rats per
group to achieve statistical significance. To account for
potential attrition, we enrolled 10 rats per group.
All data were performed using SPSS for 17.0 for Win-
dows. All data generated or analysed during this study
are included in this published article (Additional file 1).
The measurement data were presented as means ±
standard deviation (SD), and in the case of categorical
variables, frequencies were used. We used the Shapiro-
Wilk test to analyze normal distribution. Differences of
baseline parameters, time to CA, time to first heartbeat,
time to ROSC, blood gas parameters, lung wet-to-dry
ratio, and the ratio of damaged alveoli in the three
groups were compared by one-way analysis of variance.
We used the least significant difference test for the data
that had homogeneity of variance, and the Dunnett’s T3
test was used for the data that exhibited heterogeneity of
variance. Differences of hemodynamic parameters in ani-
mals were analyzed by two-way, repeated-measures ana-
lysis of variance, and Bonferroni post hoc analysis when
significance was achieved. P value < 0.05 was considered
significant. Fisher probabilities in a 3 × 2 table were used
for analyzing success resuscitation rates and survival
rates, and P value < 0.017 was considered significant in
post hoc multiple comparisons.
Results
Baseline values
There were no differences observed in weight, baseline
hemodynamic metrics, or baseline blood gas values
among the groups (Table 1).
Resuscitation outcomes
All animas in each group experienced CA for approxi-
mately 3 min, and no significant difference was found
among the three groups in the time to CA (P = 0.986;
Table 2). The numbers of animals with ROSC in the EL,
E, and L groups were 10, 8, and 2, respectively; the three
groups displayed different ROSC rates (10 rats in each
group; P < 0.001; Table 2). The numbers of animals sur-
viving to 60 min were 10, 4, and 2, in the EL, E, and L
groups, respectively. The EL, E, and L groups thus dis-
played a difference in rates of survival (P = 0.001;
Table 2). The groups also demonstrated differences in
the time to return of pulse (P < 0.001; Table 2) and the
time to ROSC (P = 0.001; Table 2). The time to ROSC of
the survived rats, and its distribution in the three
groups, is presented in Fig. 1.
Hemodynamic measures
Hemodynamic values such as CPP, MAP, HR, and RPP
for the three groups are presented in Fig. 2. Significant
differences were seen in CPP, MAP, HR, and RPP among
the EL, E, and L groups (P < 0.05). Further comparisons
in the first 3 min, e.g., the CPP and MAP, but not the
RPP or HR, in the EL group were higher than that in the
E or L group (P < 0.05).
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Lung wet-to-dry weight ratio
The EL, E, and L groups showed differences in lung wet-
to-dry weight ratios (5.1 ± 0.3, 6.0 ± 0.4, and 5.7 ± 0.6, re-
spectively; P = 0.005). The ratio in the EL group was sig-
nificantly lower than that of the E group (P = 0.001; Fig. 3).
Lung histological examination
In the EL group, there was no evidence of alveolar struc-
tural damage, edema, or hemorrhage. In the E group,
there were numerous erythrocytes in the alveolar field,
accompanied by altered alveolar structures. In the L
group, some alveoli could be identified, and there were
numerous erythrocytes observed in the injured alveoli
(Fig. 4). The EL, E, and L groups showed differences in
the rate of injured alveoli (0.15 ± 0.07, 0.74 ± 0.08, 0.53 ±
0.31, respectively; P = 0.002). The rate of damaged alveoli
in the EL group was significantly lower than that of the
E group (P < 0.001).
Blood gas analysis
Arterial blood gas parameters at 60 min are shown in
Table 3. The EL, E, and L groups displayed significant
differences in blood gas parameters (P < 0.05). Specific-
ally, the PH, PaO2, HCO3
-, and base excess (BE) values of
the EL group were significantly higher than that of the E
group (PH: EL vs. E, P = 0.021; PaO2: EL vs. E, P < 0.001;
HCO3
−: EL vs. E, P = 0.004; BE: EL vs. E, P = 0.004). In
addition, the PH values and BE in the EL group were
significantly higher than that of the L group (PH: EL vs.
L, P = 0.024; BE: EL vs. L, P = 0.01). The blood lactate
value in the EL group was significantly lower than
that of the E or L group (EL vs. E, P = 0.018, EL vs.
L, P = 0.001; Table 3).
Discussion
In our study of resuscitation on asphyxia-induced CA,
we demonstrated that CPP significantly improves when
rats received epinephrine therapy supplemented with
levosimendan. The EL group also exhibited a significant
reduction in lung injury and acidosis, excellent oxygen
partial pressure, and an improved survival rate com-
pared with rats that received epinephrine or levosimen-
dan alone.
CPP, calculated as aortic pressure minus right atrial
pressure during the diastolic phase of CPR, is strongly
associated with resuscitation outcomes [17, 21]. Friess et
al. reported that maintaining CPP > 20 mmHg is the pri-
mary determinant for ROSC and survival from CA [22].
Levosimendan can decrease the central venous pressure
and the systolic and diastolic pressures of the right
Table 2 Resuscitation Outcomes for EL, E and L Groups
EL group (n = 10) E group (n = 10) L group (n = 10) P value
Rate of ROSC, n (%) 10 (100%)## 8 (80%) 2 (20%)* <0.001
Survival rate, n (%) 10 (100%)*## 4 (40%) 2 (20%) 0.001
Time to CA, s 167 ± 28 167 ± 26 165 ± 19 0.986
Time to return of pulse, s 39 ± 7## 44 ± 10 99 ± 19** < 0.001
Time to ROSC, s 47 ± 7**# 81 ± 22 277 ± 10** 0.001
Normal distributed data are given as mean ± SD. The EL, E and L groups displayed differences in the rate of ROSC (P < 0.001; EL vs. E, P =0.474; EL vs. L, P = 0.001;
E vs. L, P =0.023). The EL, E and L groups displayed difference in rates of survival (P = 0.001; EL vs. E, P = 0.011; EL vs. L, P = 0.001; E vs. L, P =0.628). There were no
differences among the three groups in the time to CA (P > 0.05). The EL, E and L groups displayed differences in the time to return of pulse (P < 0.001; EL vs. E,
P =0.354; EL vs. L, P < 0.001; E vs. L, P < 0.001). The EL, E, and L groups displayed differences in the time to ROSC (P = 0.001; EL vs. E, P = 0.008; EL vs. L, P = 0.021;
E vs. L, P < 0.001), *P < 0.05, **P < 0.01, versus group E;#P < 0.05, ##P < 0.01, versus group L. ROSC indicates return of spontaneous circulation. CA indicates
cardiac arrest
Table 1 Baseline Values of Weight, Hemodynamic Metrics, and Blood Gas Values for group EL, group E and group L
EL group (n = 10) E group (n = 10) L group (n = 10) P value
Weight, g 320 ± 16 326 ± 12 332 ± 13 0.174
SBP, mmHg 113 ± 11 108 ± 7 114 ± 9 0.310
RPP, mmHg · beat · min−1 50886 ± 6330 47889 ± 3750 47997 ± 5075 0.352
CPP, mmHg 72 ± 10 69 ± 9 73 ± 7 0.695
PH 7.39 ± 0.03 7.39 ± 0.04 7.37 ± 0.04 0.248
PaO2, mmHg 369 ± 32 355 ± 40 389 ± 62 0.290
HCO3
−, mmol/L 22.6 ± 2.6 22.2 ± 2.3 24.2 ± 2.4 0.176
BE, mmol/L −2.3 ± 3.1 −2.7 ± 2.1 −1.5 ± 2.1 0.550
Lactate, mmol/L 1.1 ± 0.5 1.2 ± 0.4 1.5 ± 0.3 0.074
Normally distributed data were given as mean ± SD. No statistical difference among the 3 groups. SBP indicates systolic blood pressure. RPP indicates rate-pressure
product (systolic blood pressure × heart rate). CPP indicates coronary perfusion pressure. BE indicates base excess
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Fig. 1 A scatter plot of the time to ROSC for rats that survived to
60 min. The numbers of rats that survived to 60 min in EL, E, and L
groups were 10, 4, 2, respectively. The times to ROSC in the EL, E,
and L groups were 47 ± 7 s, 77 ± 14 s, 278 ± 11 s, respectively. The
times to ROSC in the three groups displayed statistical differences
(P < 0.001, EL vs. E, P < 0.001; EL vs. L, P < 0.001; E vs. L, P < 0.001).
n = 10 for the EL group, n = 4 for the E group, n = 2 for the L group.
ROSC: return of spontaneous circulation
Fig. 2 Hemodynamic parameters for rats that survived to 60 min. CPP (a), MAP (b), HR (c), and RPP (d) versus time for these survival rats during
the 60-min observation period are shown. The data are presented as means and SD. Significant differences are demonstrated in the values of
CPP, MAP, HR, and RPP among the EL, E, and L groups (P < 0.05). On considering the importance of the early phase for successful resuscitation,
further comparisons in the first 3 min were performed. CPP and MAP, but not RPP or HR in the EL group was higher than that of the E or L group
within the first 3 min (P < 0.05).n = 10 for the EL group, n = 4 for the E group, n = 2 for the L group. CPP = coronary perfusion pressure; MAP =mean
arterial pressure; HR = heart rate. RPP = rate-pressure product(systolic blood pressure × heart rate)
Fig. 3 Lung wet-to-dry ratio. Normal distributed data are given as
mean ± SD. The EL, E, and L groups displayed statistic differences in
wet-to-dry lung weight ratios (5.1 ± 0.3, 6.0 ± 0.4, and 5.7 ± 0.6,
respectively; P = 0.005). The ratio in the EL group was significantly
lower than that of the E group, P = 0.001
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atrium [11]. Epinephrine can constrict the peripheral
blood vessels and increase aortic pressure. Concomitant
therapy with epinephrine and levosimendan has a syner-
gistic effect on elevating CPP. In our study, CPP in the
epinephrine supplemented with levosimendan group in-
creased more significantly than the other two groups
within 3 min, with an average CPP > 20 mmHg. It may
be this synergistic effect that leads to all rats exhibiting
ROSC in the EL group, suggesting that maximizing CPP
quickly and efficiently is the key component to improv-
ing CPR outcomes. Levosimendan alone can not en-
hance CPP during CPR because of its peripheral
vasodilatory effect. The result of our study was that CPP
and the resuscitation rate of the levosimendan group
was the lowest among the three groups.
Myocardium contraction weakened when heart failure,
correlated with the decrease in extracellular Ca2+ inflow,
reduced the sarcoplasmic reticulum uptake of release of
Ca2+ and hindered the binding between troponin and
Ca2+. Levosimendan is a selective systolic calcium
sensitizer mainly used clinically for the treatment of
acute heart failure. When sudden CA occurs, synthesis
of ATP is blocked and myocardial cell cannot pump
redundant Ca2+ to the extracellular space, thereby inhi-
biting excitation contraction coupling. Myocardial cyto-
clasis then occurs due to an overload of calcium. If CPR
is implemented immediately, myocardial perfusion
would maintain calcium ion at 25 to 30% of normal
levels. Epinephrine is added at the same time to con-
strict the blood vessels to enhance CPP. In addition,
levosimendan has a direct vasodilatory effect on coron-
ary arteries and enhances coronary blood flow [23, 24].
In this case, myocardial cells decompose glucose to ob-
tain the minimal requirement of ATP to continue the
mechanism of calcium-triggered calcium release. If so,
levosimendan could exert the function of sensitization to
strengthen the contractility of myocardial cells.
Krishnamoorthy et al. [6] reported that intravenous
injection of epinephrine in healthy adult rats induced
rapid deterioration of pulmonary oxygen exchange, but
the effects were blunted by α-adrenergic receptor block-
ade. Lindberg et al. [25] showed that epinephrine caused
peripheral vasoconstriction through excitation of alpha
receptors, which increased cardiac afterload, and could
further increase left atrial and pulmonary vein pressure.
In addition, the Morelli study suggested that levosimen-
dan could expand the peripheral vascular bed and de-
crease the cardiac afterload in patients who suffer from
acute respiratory distress syndrome [26]. Bracken et al.
[27] also demonstrated that levosimendan reduced the
Fig. 4 The samples were taken from an EL, E, and L group rat’s right
middle lobe, and the view was under light microscopy. For the rats
in the EL group, the alveolar structures are normal and there is no
leukocyte or erythrocyte accumulation seen in the alveoli. In the E
group, most of the alveoli are destroyed, and their structures are
significantly altered, with numerous erythrocytes evident accompanying
the damaged alveolar framework. In the L group, some alveoli are
identified, and there are numerous erythrocytes observed in the alveoli.
The EL, E, and L groups displayed statistical differences in the rate of
damaged alveoli (0.15 ± 0.07, 0.74 ± 0.08, and 0.53 ± 0.31, respectively;
P= 0.002). The rate of damaged alveoli in the EL group was significantly
lower than that in the E group, P < 0.001. Magnification: 200× (left
panel), 400× (right panel)
Table 3 Arterial Blood Gas Parameters at 60 min
EL group (n = 10) E group (n = 10) L group (n = 10) P value
PH 7.32 ± 0.02*# 7.06 ± 0.24 7.14 ± 0.18 0.01
PaO2, mmHg 173 ± 33
** 91 ± 27 93 ± 85 0.008
HCO3
−, mmol/L 21.6 ± 1.6** 14.3 ± 5.1 19.0 ± 4.0 0.001
BE, mmol/L −4.6 ± 1.7**# −16.5 ± 8.3 −10.1 ± 4.5 0.001
Lactate, mmol/L 1.1 ± 0.5*## 8.0 ± 6.2 8.7 ± 4.0 0.002
Normal distributed data are given as mean ± SD. The EL, E and L groups demonstrated differences in blood gas values. The pH, PaO2, HCO3
− and BE values in the
EL group were higher than that in the E group (PH: EL vs. E, P = 0.021; PaO2: EL vs. E, P < 0.001; HCO3
−: EL vs. E, P = 0.004; BE: EL vs. E, P = 0.004). The PH and BE
values in the EL group were higher than that in the L group (PH: EL vs. L, P = 0.024; BE: EL vs. L, P = 0.01). The blood lactate value in the EL group were lower than
that of the E or L group (EL vs. E, P = 0.018; EL vs. L, P = 0.001). There were no differences between EL group and L group in the PaO2 and HCO3
− values (P > 0.05).
*P < 0.05, **P < 0.01, versus group E; #P < 0.05, ##P < 0.01, versus group L. BE indicates base excess
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pressure of cat pulmonary arteries. In the present
experiment, rats receiving epinephrine supplemented
with levosimendan showed less lung injury and acidosis
after resuscitation. This result suggests that the vasodila-
tory effects of levosimendan could partly offset the
epinephrine-induced side effects. The complementary
effect of these two medications could xhave possible
beneficial CPR outcomes CPR outcomes.
Many α-agonist agents have been shown to increase
CPP. However, no placebo-controlled study has shown
that the use of any vasoconstrictor during CA can
increase survival rates [14]. Kelm et al. [12] reported that
levosimendan combined with vasopressin administration
during CPR resulted in increased cerebral blood flow
and improved neurological outcomes. However, their
study failed to demonstrate that the combination of the
above two medications can facilitate ROSC in a rat
model of asphyctic CA. Kosmidou et al. [13] showed
that 12 μg/kg levosimendan combined with 20 μg/kg
epinephrine only improved 24-h neurological outcomes
in a swine model of asphyctic CA. However, Koudouna
et al. [14] reported that the same dose of levosimendan
combined with epinephrine significantly improved CPP
and initial resuscitation success in a swine model of ven-
tricular fibrillation CA. In our study, 10 μg/kg epineph-
rine combined with 12 μg/kg levosimendan significantly
improved survival rates in a rat model of asphyctic CA.
The difference of species and dosage may result in
encouraging results our study has observed. Neverthe-
less, the ideal dosage of each medication to produce the
best effect is still not clear, which requires additional
studies on the dosage-response relationship of epineph-
rine and levosimendan on CPR.
It should be recognized that this study has limitations.
Our study focused exclusively on short-term survival re-
sults and does not address neurological outcomes and
long-term survival outcomes, which are the end point of
cardiopulmonary cerebral resuscitation in clinical practice.
We will explore these parameters in future experiments.
Conclusion
As a calcium-sensitizer agent, levosimendan improved
initial resuscitation outcomes in asphyxia-induced CA
when administered with epinephrine during CPR. These
effects may contribute to increased coronary perfusion
flow and reduced lung injury and acidosis. Our study
has suggested that levosimendan can be selected as a
promising alternative supplement agent to epinephrine
during CPR for asphyxia-induced CA.
Additional file
Additional file 1: All data generated or analysed during this study. (ZIP 67 kb)
Abbreviations
BE: Base excess; CA: Cardiac arrest; CPP: Coronary perfusion pressure;
CPR: Cardiopulmonary resuscitation; HR: Heart rate; MAP: Mean arterial
pressure; ROSC: Return of spontaneous circulation; RPP: Rate-pressure
product
Acknowledgements
We would like to thank Zhengqian Li from Peking University Third Hospital
of China for revising the manuscript and Corey Astrom of the University of
Florida for her editorial assistance.
Funding
This work was supported by the Natural Science Foundation of Zhejiang
province, China (no. Y13H090050). This funding was used for the design of
the study and the collection of data.
Availability of data and materials
All data generated or analysed during this study are included in this
published article (Additional file 1).
Authors’ contributions
BW: Contribution: Design the study, conduct the study, analyse the data, and
write the manuscript. YP: Contribution: Design the study and write the
manuscript. SZ: Contribution: Conduct the study and write the manuscript.
NB: Contribution: Conduct the study and study data collection. LP:
Contribution: Conduct the study. JD: Contribution: Conduct the study. XX:
Contribution: Design the study, analyse the data, and write the manuscript.
QW: Contribution: Write the manuscript and critical manuscript review,
writing and preparation. All authors read and approved the final manuscript.
Competing interests




This experiment was approved by the Ethics Committee of the Wenzhou
Medical University (Wenzhou, Zhejiang, China) in accordance with the
Guideline for the Care and Use of Laboratory Animals.
Author details
1Department of Anesthesiology, The First Affiliated Hospital, Wenzhou
Medical University, Wenzhou City, Zhejiang Province, China. 2Department of
Anesthesiology, College of Medicine, University of Florida Shands Hospital,
Gainesville, FL, USA. 3The First Affiliated Hospital, Wenzhou Medical
University, South Baixiang Rd, Wenzhou City, Zhejiang Province 325000,
China.
Received: 21 April 2016 Accepted: 23 January 2017
References
1. Meyer L, Stubbs B, Fahrenbruch C, et al. Incidence, causes, and survival
trends from cardiovascular-related sudden cardiac arrest in children and
young adults 0 to 35 years of age: a 30-year review. Circulation. 2012;126:
1363–72.
2. Xanthos T, Pantazopoulos I, Demestiha T, Stroumpoulis K. Epinephrine in
ventricular fibrillation: friend or foe? A review for the emergency nurse.
J Emerg Nurs. 2011;37:408–12.
3. Callaway CW. Epinephrine for cardiac arrest. Curr Opin Cardiol. 2013;28:36–42.
4. Ditchey RV, Lindenfeld J. Failure of epinephrine to improve the balance
between myocardial oxygen supply and demand during closed-chest
resuscitation in dogs. Circulation. 1988;78:382–9.
5. Tang W, Weil MH, Sun S, Noc M, Yang L, Gazmuri RJ. Epinephrine increases
the severity of post resuscitation myocardial dysfunction. Circulation. 1995;
92:3089–93.
6. Krishnamoorthy V, Hiller DB, Ripper R, et al. Epinephrine induces rapid
deterioration in pulmonary oxygen exchange in intact, anesthetized rats:
a flow and pulmonary capillary pressure-dependent phenomenon.
Anesthesiology. 2012;117:745–54.
Wu et al. BMC Anesthesiology  (2017) 17:18 Page 7 of 8
7. Neumar RW, Shuster M, Callaway CW, et al. Part 1: executive summary: 2015
American Heart Association guidelines update for cardiopulmonary
resuscitation and emergency cardiovascular care. Circulation. 2015;132:
S315–67.
8. Jamali IN, Kersten JR, Pagel PS, Hettrick DA, Warltier DC. Intracoronary
levosimendan enhances contractile function of stunned myocardium.
Anesth Analg. 1997;85:23–9.
9. Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during
levosimendan infusion in congestive heart failure. Clin Pharmacol Ther.
2000;68:522–31.
10. Figgit DP, Gillies PS, Goa KL. Levosimendan. Drugs. 2001;61:613–27.
11. Tassani P, Schad H, Heimisch W, et al. Effect of the calciumsensitizer
levosimendan on the performance of ischaemicmyocardium in
anaesthetised pigs. Cardiovascular Drugs Ther. 2002;16:435–41.
12. Kelm RF, Wagenfuhrer J, Bauer H, Schmidtmann I, Engelhard K, Noppens RR.
Effects of levosimendan on hemodynamics, local cerebral blood flow,
neuronal injury, and neuro inflammation after asphyctic cardiac arrest in
rats. Crit Care Med. 2014;42:e410–9.
13. Kosmidou ML, Xanthos T, Chalkias A, et al. Levosimendan improves
neurological outcome in a swine model of asphyxial cardiac arrest. Heart
Lung Circ. 2015;24:925–31.
14. Koudouna E, Xanthos T, Bassiakou E, et al. Levosimendan improves the
initial outcome of cardiopulmonary resuscitation in a swine model of
cardiac arrest. Acta Anaesthesiol Scand. 2007;51:1123–9.
15. Jin Z, Xia Y, Xia F, et al. Epinephrine administration in lipid-based
resuscitation in a rat model of bupivacaine-induced cardiac arrest: optimal
timing. Reg Anesth Pain Med. 2015;40:223–31.
16. Li Z, Xia Y, Dong X, et al. Lipid resuscitation of bupivacaine toxicity: long-
chain triglyceride emulsion provides benefits over long- and medium-chain
triglyceride emulsion. Anesthesiology. 2011;115:1219–28.
17. Paradis NA, Martin GB, Rivers EP, et al. Coronary perfusion pressure and the
return of spontaneous circulation in human cardiopulmonary resuscitation.
JAMA. 1990;263:1106–13.
18. McCaul CL, McNamara PJ, Engelberts D, et al. Epinephrine increases
mortality after brief asphyxial cardiac arrest in an in vivo rat model. Anesth
Analg. 2006;102:542–8.
19. Di Gregorio G, Schwartz D, Ripper R, et al. Lipid emulsion is superior to
vasopressin in a rodent model of resuscitation from toxin-induced cardiac
arrest. Crit Care Med. 2009;37:993–9.
20. Murata T, Nakazawa H, Mori I, Ohta Y, Yamabayashi H. Reperfusion after a
two-hour period of pulmonary artery occlusion causes pulmonary necrosis.
Am Rev Respir Dis. 1992;146:1048–53.
21. Reynolds JC, Salcido DD, Menegazzi JJ. Coronary perfusion pressure and
return of spontaneous circulation after prolonged cardiac arrest. Prehosp
Emerg Care. 2010;14:78–84.
22. Friess SH, Sutton RM, Bhalala U, et al. Hemodynamic directed
cardiopulmonary resuscitation improves short-term survival from ventricular
fibrillation cardiac arrest. Crit Care Med. 2013;41:2698–704.
23. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J.
Coronary vasorelaxant effect of levosimendan, a new inodilator with
calcium-sensitizing properties. J Cardiovasc Pharmacol. 1998;31:741–9.
24. Kivikko M, Lehtonen L. Levosimendan: a new inodilatory drug for the
treatment of decompensated heart failure. Curr Pharm Des. 2005;11:435–55.
25. Lindberg L, Liao Q, Steen S. The effects of epinephrine/norepinephrine on
end-tidal carbon dioxide concentration, coronary perfusion pressure and
pulmonary arterial blood flow during cardiopulmonary resuscitation.
Resuscitation. 2000;43:129–40.
26. Morelli A, Teboul JL, Maggiore SM, et al. Effects of levosimendan on right
ventricular afterload in patients with acute respiratory distress syndrome: a
pilot study. Crit Care Med. 2006;34:2287–93.
27. De Witt BJ, Ibrahim IN, Bayer E, et al. Ananalysis of responses to
levosimendan in the pulmonary vascular bed of the cat. Anesth Analg.
2002;94:1427–33.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wu et al. BMC Anesthesiology  (2017) 17:18 Page 8 of 8
